NCT01830010已完成1 期
A Two-part, Single- and Two Arm Randomized, Open-label Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy (in Part 2 Only) of KRP203 in Patients Undergoing Stem Cell Transplant for Hematological Malignancies
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 23
- 试验地点
- 9
- 主要终点
- Number of participants with Adverse Events as a Measure of safety
研究概览
简要总结
Two part study to evaluate the safety, tolerability, pharmacokinetics, and efficacy (in Part 2 only) of KRP203 in patients undergoing allogeneic hemopoietic stem cell transplant for hematological malignancies
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Parallel
- 主要目的
- Prevention
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 65 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- 未提供
排除标准
- •Resting heart rate below 55
- •Significant cardiac disease (such as arrhytmia, heart failure) or any significant condition which in the investigators opinion would make the patient ineligible
- •Previous allogeneic HSCT
- •Any drug required that is not compatible with KRP203 (e.g. beta-blockers or anti-thymocyte globulin)
结局指标
主要结局
Number of participants with Adverse Events as a Measure of safety
时间窗: 111 days
Safety and tolerability of KRP203 in patients undergoing allogeneic hematopoetic stem cell transplant for hematological malignancies
次要结局
- Plasma Pharmacokinetics of KRP203: Area under the Plasma Concentration-time Curve (AUC)(111 days)
- Plasma Pharmacokinetics (PK) of KRP203: Observed Maximum Plasma Concentration Following Drug Administration (Cmax)(111 days)
- Plasma Pharmacokinetics (PK) of KRP203: Time to reach the maximum concentration after drug administration(111 days)
- GVHD-free, relapse free survival(2 years post transplant)
研究者
研究点 (9)
Loading locations...
相似试验
已完成
2 期
A Study to Evaluate SAGE-217 in Participants With Bipolar I/II Disorder With a Current Major Depressive EpisodeBipolar Disorder IBipolar Disorder IIMajor Depressive EpisodeNCT03692910Biogen35
已完成
1 期
Evaluate the Safety and Tolerability, as Well as the Pharmacokinetic and Pharmacodynamic Profiles of Single and Multiple Doses of Eplontersen Administered Subcutaneously to Healthy Volunteers and Patients With Hereditary Transthyretin-Mediated Amyloidosis (hATTR ).Healthy VolunteershATTR AmyloidosisNCT03728634Ionis Pharmaceuticals, Inc.47
终止
1 期
An Open-Label Study of the Effect of Telaprevir in Combination With Peginterferon Alfa-2b and Ribavirin in Pediatric Subjects Infected With Hepatitis C VirusHepatitis CNCT01701063Vertex Pharmaceuticals Incorporated42
已完成
1 期
A Healthy Volunteer Study Evaluating the the Safety, Tolerability, and Pharmacokinetics of RT234Healthy VolunteerNCT05567367Respira Therapeutics, Inc.31
终止
2 期
A Clinical Trial of BMX-010 in Adult Subjects With Atopic DermatitisAtopic DermatitisNCT05491447BioMimetix JV, LLC103